DiaGenic has in its pipeline two products in development.

 

MCItect®

MCItect® is intended to be used as an aid to diagnose Alzheimer's disease at an earlier stage of the disease, a stage called Mild Cognitive Impairment (MCI) due to Alzheimer's disease.

The development of MCItect® would help increase the chances of a correct diagnosis at this earlier stage of the disease and could also help drug companies that are developing new drugs to try to attack the disease earlier.

PDtect®

Parkinson's disease is the second most common neurodegenerative disease after Alzheimer's disease. Correct diagnosis is crucial in the management of Parkinson's disease but there is currently no test available to aid the diagnosis of the disease. For development of new drugs early disease detection is also critical.
The intention with PDtect® is to aid in the diagnosis of Parkinson's disease at the earliest possible stage of the disease to help improve disease management and help developing new and improved drugs for the disease.